Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Tesamorelin

Abstract

In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Grunfeld, C. et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 118, e20–e28 (2008).

    Article  CAS  Google Scholar 

  2. Grunfeld, C. et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 24, 1717–1726 (2010).

    Article  Google Scholar 

  3. Crane, H. M. et al. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. HIV Med. 9, 780–786 (2008).

    Article  CAS  Google Scholar 

  4. Koutkia, P. & Grinspoon, S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu. Rev. Med. 55, 303–317 (2004).

    Article  CAS  Google Scholar 

  5. Rietschel, P. et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metabol. 86, 504–510 (2001).

    CAS  Google Scholar 

  6. Lo, J. et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300, 509–519 (2008).

    Article  CAS  Google Scholar 

  7. Stanley, T. L. et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab. 96, 150–158 (2011).

    Article  CAS  Google Scholar 

  8. Koutkia, P. et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 292, 210–218 (2004).

    Article  CAS  Google Scholar 

  9. Ferdinandi, E. S. et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin. Pharmacol. Toxicol. 100, 49–58 (2007).

    Article  CAS  Google Scholar 

  10. US Food and Drug Administration. FDA labelling information — Egrifta (tesamorelin for injection) FDA website [online], (2010).

  11. Falutz, J. et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N. Engl. J. Med. 357, 2359–2370 (2007).

    Article  CAS  Google Scholar 

  12. Falutz, J. et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22, 1719–1728 (2008).

    Article  CAS  Google Scholar 

  13. Falutz, J. et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J. Clin. Endocrinol. Metabol. 95, 4291–4304 (2010).

    Article  CAS  Google Scholar 

  14. Després, J. P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9, 452–459 (1993).

    PubMed  Google Scholar 

  15. Thörne, A. et al. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. 26, 193–199 (2002).

    Article  Google Scholar 

  16. Klein, S. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350, 2549–2557 (2004).

    Article  CAS  Google Scholar 

  17. Silverberg, M. J. et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann. Intern. Med. 150, 301–313 (2009).

    Article  Google Scholar 

  18. Loe, D. Research Update (Versant Partners, 6 Dec 2010).

  19. Maruoka, N. Daily Letter (Canaccord Genuity, 6 Dec 2010).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

C.G. was an investigator in trials of growth hormone, tesamorelin and leptin; in that capacity he received research funding from and advised Theratechnologies, EMD Serono and Amgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grunfeld, C., Dritselis, A. & Kirkpatrick, P. Tesamorelin. Nat Rev Drug Discov 10, 95–96 (2011). https://doi.org/10.1038/nrd3362

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3362

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research